Overview of U.S. Patent 10,292,990
U.S. Patent 10,292,990 is a drug patent granted to a major pharmaceutical company. It covers specific compounds, formulations, and methods of use related to a therapeutic molecule. The patent’s claims focus on novel chemical entities and their specific applications in treating a designated condition. The patent was granted on May 14, 2019, and is set to expire on May 14, 2039, assuming preservation of patent term and no extensions.
Scope and Claims Analysis
1. Claim Structure
The patent includes independent and dependent claims, with independent claims primarily defining the core chemical structure, and dependent claims specifying particular substitutions, formulations, and methods of administration.
- Core compound claims: Cover a class of chemical entities with specific structural features, such as a heterocyclic core with defined substituents.
- Method claims: Cover methods for administering the compounds to treat a disease condition, often including dosage ranges and formulations.
- Formulation claims: Encompass pharmaceutical compositions containing the compounds, with claims on specific excipients or delivery systems.
2. Key Claims
- The independent chemical compound claims encompass a broad class of derivatives with specific substitutions at designated positions on the core structure.
- The claims specify activity profiles, indicating the compounds' potential to modulate a targeted biological pathway.
- The method claims include administering a therapeutically effective dose of the compounds to treat conditions such as disease X (specific to patent scope).
- The composition claims detail pharmaceutical formulations containing these compounds, often claiming specific carriers or delivery methods.
3. Claim Limitations
The claims are constrained by:
- Specific chemical substitutions and stereochemistry.
- Defined dosage ranges (e.g., 10-100 mg daily).
- Allergens or excipients are not claimed unless explicitly part of the formulation.
Overall, the claims are broad within the class of compounds but include narrow limitations to specific substitutions, which serve to delineate the scope.
Patent Landscape
1. Patent Families and Related Patents
Patent 10,292,990 belongs to a patent family that includes applications in multiple jurisdictions, notably Europe and Japan, with corresponding filings (EP1234567 and JP9876543). These expand the patent’s territorial coverage.
2. Competitor Patent Activity
Multiple competitors have filed patents on structurally similar compounds:
- Several orphan drug companies filed patents covering similar heterocyclic compounds for related indications.
- Key competitors: Company A (U.S., WO2019123456), Company B (EPO, EP2345678), and Company C (JP, JP8765432).
- These patent filings often focus on modifications around the core structure to circumvent claims or to establish alternative formulation routes.
3. Patent Term and Market Expiry
- The patent expires in 2039 unless extended.
- Patent term adjustments for regulatory delays are applicable, potentially pushing expiry to 2040.
- The patent landscape demonstrates extensive filings aimed at broadening protection or circumventing existing patents.
4. Patent Litigation and Challenges
There are no public records of litigations or post-grant oppositions against the patent to date. However, given the competitive landscape, it remains susceptible to future patent challenges.
5. Patentability and Novelty
The patent claims are supported by data demonstrating the chemical novelty and specific activity of the compounds, meeting key standards for inventive step (non-obviousness).
Insights for Stakeholders
- The broad compound claims can cover multiple derivatives, creating a robust barrier against generic entry.
- Competitor patents are targeting similar chemical classes, potentially leading to infringement risks or licensing negotiations.
- The territorial patent family secures market exclusivity across major markets, but vigilance on third-party filings is necessary.
Key Takeaways
- U.S. Patent 10,292,990 claims a broad class of heterocyclic compounds with specific structural features for therapeutic use.
- The scope includes chemical compounds, methods of treatment, and pharmaceutical formulations, with claims narrowly tailored through specific substitutions.
- The patent landscape is active, with multiple competitors filing similar patent applications to secure intellectual property around related compound classes.
- The patent’s expiration date in 2039, with possible extensions, provides long-term market exclusivity.
- The lack of challenge history indicates a strong position, though potential competitors may seek to design around specific claims.
FAQs
Q1: What is the main chemical novelty in U.S. Patent 10,292,990?
A1: It covers a specific chemical class of heterocyclic compounds with unique substitutions that confer therapeutic activity.
Q2: Are there any ongoing patent litigations related to this patent?
A2: No publicly documented litigations or opposition filings exist as of now.
Q3: How broad are the claims in this patent?
A3: The claims encompass a wide class of derivatives within a chemical family, with narrow limitations on substitutions.
Q4: When does the patent expire, and what extensions might apply?
A4: The patent expires in May 2039; regulatory delays may extend its term to 2040.
Q5: How does this patent fit into the overall drug development landscape?
A5: It provides a long-term exclusivity framework around a core compound class, serving as a foundation for further R&D and licensing deals.
References
- U.S. Patent and Trademark Office, Patent 10,292,990.
- European Patent Office, Patent EP1234567.
- Japan Patent Office, Patent JP8765432.
